このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Pulse Biosciences マネジメント

マネジメント基準チェック /24

Pulse Biosciences'の CEO はBurke Barrettで、 May2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の0.02%を直接所有しており、その価値は$ 233.82K 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と6.8年です。

主要情報

Burke Barrett

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.02%
経営陣の平均在職期間	2.5yrs
取締役会の平均在任期間	6.8yrs

経営陣の近況

Recent updates

What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?

Jan 20

Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication

Jan 12

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Dec 16

CEO（最高経営責任者

Burke Barrett (60 yo)

less than a year

在職期間

Mr. Burke T. Barrett is President & CEO of Pulse Biosciences, Inc. from May 14, 2024 and also serves as its Director since May 2024. Mr. Barrett served as President, Secretary and Director of CardioFocus,...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Duggan	Executive Co-Chairman	6.8yrs	US$257.41k	69.46% $ 732.5m
Darrin Uecker	CTO & Director	2yrs	US$5.39m	0.25% $ 2.6m
Mitchell Levinson	Chief Strategy Officer	3.1yrs	US$1.69m	0.22% $ 2.3m
Kevin Danahy	Chief Commercial Officer	less than a year	US$5.86m	0.060% $ 628.6k
Burke Barrett	President	less than a year	データなし	0.020% $ 209.4k
Edison Manuel	Vice President of Operations	7.4yrs	データなし	データなし
Richard Nuccitelli	Chief Science Officer	9.8yrs	データなし	データなし
Kenneth B. Stratton	General Counsel & Corporate Secretary	3.3yrs	データなし	データなし
Patty Perla	Vice President of Human Resources	4.7yrs	データなし	データなし
David Danitz	Senior Vice President of Engineering	3yrs	データなし	データなし
Gansevoort Dunnington	Chief Medical Officer	1.3yrs	データなし	データなし
Niv Ad	Chief Science Officer of Cardiac Surgery	less than a year	データなし	データなし

2.5yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: PLSEの経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Duggan	Executive Co-Chairman	6.8yrs	US$257.41k	69.46% $ 732.5m
Darrin Uecker	CTO & Director	9yrs	US$5.39m	0.25% $ 2.6m
Burke Barrett	President	less than a year	データなし	0.020% $ 209.4k
Richard van den Broek	Independent Director	4.1yrs	US$208.89k	0% $ 0
Paul LaViolette	Independent Co-Chairman of the Board	less than a year	データなし	データなし
Mahkam Zanganeh	Independent Director	7.6yrs	US$173.00k	1.33% $ 14.0m
Manmeet Soni	Lead Independent Director	6.8yrs	US$180.07k	0% $ 0

6.8yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: PLSEの取締役会は経験豊富であると考えられます ( 6.8年の平均在任期間)。

Pulse Biosciences マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought US$86k worth of stock

Pulse Biosciences, Inc Announces CEO Changes

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Executive Chairman exercised options to buy US$382k worth of stock.

Recent updates

Pulse Biosciences, Inc. announced delayed 10-Q filing

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Small Cap Comp Value Index

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought US$86k worth of stock

Pulse Biosciences Stock: Signs Of Life Following Q1 Update

Pulse Biosciences, Inc Announces CEO Changes

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

New major risk - Financial position

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman exercised options to buy US$382k worth of stock.

Executive Chairman recently bought US$1.1m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought US$105k worth of stock

Executive Chairman exercised options to buy US$68k worth of stock.

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Executive Chairman exercised options to buy US$881k worth of stock.

Executive Chairman exercised options to buy US$36m worth of stock.

Independent Director exercised options to buy US$543k worth of stock.

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Strategy Officer & Director recently bought US$70k worth of stock

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

Pulse Biosciences, Inc. Announces Executive Changes

Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO

Consensus revenue estimates fall by 31%

Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System

Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index

Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million.

Consensus forecasts updated

Price target decreased to US$11.17

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc

Consensus forecasts updated

Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky

Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022

Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission

Price target decreased to US$35.33

Price target decreased to US$35.33

Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

Forecast to breakeven in 2024

Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?

Consensus forecasts updated

Price target decreased to US$37.95

Independent Chairman of the Board recently bought US$50m worth of stock

Pulse Biosciences, Inc. Announces First CellFX Procedure Performed in Canada

Pulse Biosciences Announces Health Canada Approval for CellFX® System

Pulse Biosciences gets Health Canada approval for CellFX System

マネジメント基準チェック /24